{"url_path":"/sec/orka/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-063481-index.html","accession_number":"0001213900-26-063481","cik":"0000907654","ticker":"ORKA","issuer_name":"Oruka Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-063481-index.html","primary_entity_key":"0000907654","primary_entity_name":"Oruka Therapeutics, Inc."},"word_count":240,"has_tables":true,"body_markdown":"**Item 8.01. Other Events.**\n\n** **\n\nOn May 29, 2026, Oruka Therapeutics, Inc. (the “Company”)\nentered into the First Amendment to IL-23 License Agreement (the “Amendment”), amending the IL-23 License Agreement dated\nas of December 17, 2024 (the “License Agreement”), by and between the Company and Paragon Therapeutics, Inc. (“Paragon”).\nPrior to the Amendment, the Company’s Field did not include inflammatory bowel disease. The Amendment, among other things, expands\nthe definition of “Field” to encompass all therapeutic, prophylactic, palliative and diagnostic uses, subject to the restriction\nthat the Company will not dose a human patient in a clinical trial of ORKA-001 for inflammatory bowel disease as part of a combination\nuntil June 1, 2028 or as a monotherapy until June 1, 2030 (the “Monotherapy Dosing Restriction”). In the event the Company\nor a licensee of Paragon’s retained rights under the License Agreement consummates a material transaction, including a\nchange of control of the Company or such licensee, then any remaining restrictions outside of the initial definition of “Field”\nset forth in the Monotherapy Dosing Restriction shall remain in effect only until June 1, 2028 and thereafter terminate and be of no further\nforce or effect.\n\n \n\nThe foregoing is a brief description of the terms and conditions of\nthe Amendment and do not purport to be complete. The description is qualified in its entirety by reference to the complete text of the\nAmendment, a copy of which is attached hereto as Exhibit 10.1."}